NCT03930953 2026-02-19
A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)
Celgene
Phase 1/2 Active not recruiting
Clinical Trials
20 trialsNCT04809467 2026-02-04
topMIND
Incyte Corporation
Phase 1/2 Terminated
NCT05222555 2026-01-16
MINDway
Incyte Corporation
Phase 1/2 Active not recruiting
NCT04680052 2025-12-22
InMIND
Incyte Corporation
Phase 3 Active not recruiting
NCT04661007 2025-12-18
J-MIND
Incyte Corporation
Phase 1/2 Active not recruiting
NCT05429268 2025-12-10
firmMIND
Incyte Corporation
Phase 3 Active not recruiting
NCT06465433 2025-12-10
Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab
Incyte Corporation
Phase 2 Recruiting
NCT04607772 2025-10-03
Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
Karyopharm Therapeutics Inc
Phase 1/2 Withdrawn
NCT04824092 2025-09-08
frontMIND
Incyte Corporation
Phase 3 Active not recruiting
NCT04981795 2024-12-10
realMIND
Incyte Corporation
Recruiting
NCT04134936 2024-10-16
Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL
MorphoSys AG
Phase 1 Completed
NCT05328102 2024-04-30
Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)
Xencor, Inc.
Phase 2 Terminated
NCT01685008 2023-11-07
Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL)
MorphoSys AG
Phase 2 Completed
NCT02399085 2023-10-23
L-MIND
MorphoSys AG
Phase 2 Completed
NCT05205252 2023-08-15
ARIA
Ipsen
Phase 1/2 Withdrawn
NCT02639910 2021-12-20
COSMOS
MorphoSys AG
Phase 2 Completed
NCT04882163 2021-10-05
Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma
Celgene
Phase 1/2 Withdrawn
NCT04300803 2020-08-28
Expanded Access Program for Tafasitamab (MOR00208) in R/R DLBCL
MorphoSys AG
Approved for marketing
NCT01685021 2018-02-22
Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL)
MorphoSys AG
Phase 2 Terminated
NCT01161511 2014-04-21
Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia
Xencor, Inc.
Phase 1 Completed